Table 2. Baseline characteristics at HIV treatment initiation.
| Characteristics | Total | HIV Outpatient Clinic | Primary Health Clinic |
|---|---|---|---|
| n = 800 | n = 600 | n = 200 | |
| BASELINE CHARACTERISTICS AT HIV TREATMENT INITIATION1 | |||
| Gender, n (%) | |||
| Male | 275 (34.4) | 206 (34.3) | 69 (34.5) |
| Female | 525 (65.6) | 394 (65.7) | 131 (65.5) |
| Age, n (%) | |||
| 18–30 | 273 (34.1) | 206 (34.3) | 67 (33.5) |
| 31–40 | 324 (40.5) | 233 (38.8) | 91 (45.5) |
| 41–50 | 141 (17.6) | 112 (18.7) | 29 (14.5) |
| >50 | 62 (7.8) | 49 (8.2) | 13 (6.5) |
| Age, median (IQR) | 34 (28–41) | 34 (29–39) | 34 (28–41) |
| Baseline ART Regimen, n (%) | |||
| 3TC-TDF-EFV | 663 (82.9) | 506 (84.3) | 157 (78.5) |
| 3TC-TDF-NVP | 62 (7.8) | 33 (5.5) | 29 (14.5) |
| Other | 75 (9.4) | 61 (10.2) | 14 (7.0) |
| Baseline CD4 Count, n (%) | |||
| ≤100 cells/mm3 | 248 (31.0) | 192 (32.0) | 56 (28.0) |
| 101–200 cells/mm3 | 263 (32.9) | 202 (33.7) | 61 (30.5) |
| 201–350 cells/mm3 | 261 (32.6) | 181 (30.2) | 80 (40.0) |
| >351 cells/mm3 | 28 (3.5) | 25 (4.2) | 3 (1.5) |
| Baseline CD4 Count, median (IQR) | 151 (70–240) | 148 (61–237) | 162 (87–257) |
ART: antiretroviral therapy, 3TC: stavudine, TDF: tenofovir, EFV: efavirenz, NVP: nevirapine
1All the baseline characteristics were matched using propensity scores